Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 14, 2011BMJ

Implantable medical device regulation in Europe often relies on short-term studies with surrogate endpoints, transferring the responsibility for proof of safety and clinical efficacy to follow-up.

View Full Paper
Ask AI
Bookmark
Share

Design

Editorial

Key result

Implantable medical device regulation in Europe often relies on short-term studies with surrogate endpoints, transferring the responsibility for proof of safety and clinical efficacy to follow-up.

Authors

AFAlan G. FraserMKMitchell W. KrucoffRBRalph G. Brindis

Discussion

Loading...

Member takes

Overview

Device approvals relying on short-term surrogates demand post-market vigilance; leaves open the need for extended trials and regulatory harmonization.

Key Points

Key points are not available for this paper at this time.

Cite This Study

Fraser et al. (2011) reported an editorial. Implantable medical device regulation in Europe often relies on short-term studies with surrogate endpoints, transferring the responsibility for proof of safety and clinical efficacy to follow-up.

synapsesocial.com/papers/6a210db13fc57ec05c1e3827https://doi.org/10.1136/bmj.d2952
View Full Paper
Ask AI
Bookmark
Share